Are you a financial expert?Login
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup

BAFNAPHARM

0
+0 (0%)
Updated 05:30 01/01 IST

BAFNAPHARM Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for BAFNAPHARM
Disclaimer
0% Bullish
0% Bearish

BAFNAPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See BAFNAPHARM Share Price Targets >>

BAFNAPHARM Ratings

Long term BAFNAPHARM rating by FrontPage users
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
0/5 (0 Ratings)0
Find answers to all your questions on live BAFNAPHARM message board: Is BAFNAPHARM buy or sell? Should I buy BAFNAPHARM shares? Why are BAFNAPHARM shares falling? Should I invest in BAFNAPHARM stock?

  1. Home
  2. BAFNAPHARM Forum

BAFNAPHARM Share Price Discussion

hourglass_empty
No posts yet.
This service may be new or inactive. Please check back later.
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
Join FrontPage

  • BAFNAPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization66.25
    Enterprise Value110.09
    Price to Earnings9.01
    Price to Book Value1.63
    Return on Capital Employed-0.09
    Return on Equity-0.41
    Face Value10
    Dividend YieldNA

  • BAFNAPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    May 3113.213.210.9511.1
    May 3011.4121112
    May 298.610.05810
    May 288.28.57.78.4
    May 278.38.37.958.2

  • BAFNAPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹8.51
    30 Day Moving Average₹8.67
    50 Day Moving Average₹9.18
    100 Day Moving Average₹9.78
    200 Day Moving Average₹12.5

  • BAFNAPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue75.664.960.16
    Operating Profit-5.05-5.22-0.03
    Profit Before Tax-14.28-19.3-0.26
    Net Income-16.45-18.47-0.11

  • BAFNAPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds40.5340.98-0.01
    Total Liabilities86.98126.17-0.31
    Total Assets127.51167.15-0.24

  • BAFNAPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity-13.134.34-4.03
    Cash from Investing Activity37.791.0634.65
    Cash from Financing Activity-30.65-5.434.64
    Net Cash Flow-5.98-0.04148.5

  • BAFNAPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.13-0.11
    Return on Equity-0.41-0.45
    Return on Capital Employed-0.09-0.06

  • BAFNAPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.25
    3 Year CAGR Growth in Operating Profit0.73
    3 Year CAGR Growth in EBIDTA-1.16
    3 Year CAGR Growth in Net Income-3.69
    3 Yr CAGR Growth - Diluted EPS-3.12

  • BAFNAPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.55
    5 Year CAGR Growth in Operating Profit-1.24
    5 Year CAGR Growth in EBIDTA-1.16
    5 Year CAGR Growth in Net Income-5.24
    3 Yr CAGR Growth - Diluted EPS-4.34

  • BAFNAPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
Privacy•Terms•••
FrontPage © 2020